Rituximab Versus Conventional Therapy for Remission Induction in Eosinophilic Granulomatosis With Polyangiitis : A Randomized Controlled Trial.

Background: Eosinophilic granulomatosis with polyangiitis (EGPA) is an eosinophilic antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Rituximab has emerged as the standard of care in other types of ANCA-associated vasculitis, but controlled studies on its use in EGPA are yet lacking.

Objective: To compare rituximab with conventional strategy for the induction of remission in patients with EGPA.

Practical management of rheumatic immune-related adverse events occurring with immune checkpoint inhibitors: A narrative review.

Immune checkpoint inhibitors (ICIs) have dramatically changed the management of cancer and their indications are expanding, leading to an increase in immune-related adverse events (irAEs). Recently, attention has focused on previously underestimated rheumatic irAEs, including inflammatory arthritis (IA), polymyalgia rheumatica-like phenotypes and Sicca syndrome, but also fasciitis, and rare but severe immune mediated myositis, with a possible association with myasthenia-like symptoms or myocarditis. Rheumatic irAEs may have a prolonged course and affect a patient's quality of life.

Determinants of social participation in patients living with systemic lupus erythematosus: the Psy-LUP multicentre study.

Objective: Systemic lupus erythematosus (SLE) can negatively impact patients' social participation. The aim of this study was to identify the determinants of social participation in patients with SLE.

Methods: A cross-sectional evaluation was carried out in 100 adult outpatients with SLE enrolled in the multicentre psychosocial lupus (Psy-LUP) study.

Maintenance of Remission After Tocilizumab Withdrawal in Patients With Glucocorticoid-Dependent Polymyalgia Rheumatica.

Objective: The SEMAPHORE trial evaluated the efficacy and safety of tocilizumab (TCZ) treatment in patients with glucocorticoid (GC)-dependent polymyalgia rheumatica (PMR). TCZ reduced GC dose and disease activity at week 24. This study aimed to assess relapse rates after stopping TCZ treatment in patients achieving remission at week 24.

[Non-pharmacological interventions: A new paradigm and opportunities for internists].

The notion of non-pharmacological interventions (NPI) has been used by healthcare researchers since 1975, and is cited in numerous reports by French, European and international healthcare authorities, such as the WHO since 2003 and the HAS since 2011. However, it was only recently that a collaborative initiative of consensus was launched to address the lack of consensus on how to define and evaluate these health practices, amplified by the media controversy surrounding these practices during the COVID-19 episode. Indeed, in 2021, the launch of a collaborative and open research program responding to international scientific expectations in the healthcare field and to the specificities of these immaterial, personalized and targeted healthcare solutions has finally been initiated.

GNS561 (ezurpimtrostat), a small basic lipophilic molecule, prevents lupus phenotype in a pristane-induced lupus mouse model.

Background And Purpose: Systemic lupus erythematosus is an autoimmune, multisystemic disease affecting all organs in the body. Accrued evidence has elucidated a role for autophagy in the onset and severity of systemic lupus erythematosus. The antimalarial drug hydroxychloroquine constitutes the cornerstone of standard of care for systemic lupus erythematosus, together with glucocorticoids and immunosuppressants or biologics, and all accompanied by various side effects.

Analysis of humoral and cellular responses after vaccination against SARS-CoV-2 in patients with immune-mediated diseases.

Background: Patients with autoimmune disease (AID) or immunodepression (ID), particularly those treated with anti-CD20, have an increased risk of COVID-19 infection.

Objective: To characterise the humoral and cellular immune responses against specific antigens of SARS-CoV-2 in immunocompromised patients, as well as their correlation and determinants.

Methods: This retrospective study was conducted in outpatients with AID and/or ID for which an assessment of their humoral and cellular response was carried out and analysed in relation to demographic data, comorbidities, treatments, type of vaccine and number of doses.

Risk of Serious Immune-Related Adverse Events with Various PD1 and PD-L1 Inhibitors: A Single-Institution, Real-Life, Comparative Study.

Background: Immune checkpoint inhibitors (ICIs) are responsible for causing immune-related adverse events (irAEs). The frequency and severity of irAEs depend on various factors, but the role of the molecule used remains unclear. Our aim was to assess the comparative safety profile of different programmed cell death-1 inhibitors (anti-PD1) and programmed cell death ligand-1 inhibitors (anti-PD-L1) in a real-life setting.

Cluster analysis of post-COVID-19 physical and mental health outcomes 3-6 months after SARS-CoV-2 infection: results of the French Prospective ALCOVID Cohort Study.

Objectives: This study aims to characterise the diversity of post-COVID-19 physical and mental health outcomes, known as the post-COVID-19 condition (PCC), and the determining factors 3-6 months after acute SARS-CoV-2 infection.

Design: This is a prospective cohort study.

Setting: This study took place at the European Hospital of Marseille, France.

Rare association of granulomatosis with polyangiitis with an underdiagnosed spondyloarthritis effectively treated with rituximab: A case-report.

Rationale: Associations of autoimmune diseases are rare but interesting and challenging situations from a diagnostic, pathophysiological, and therapeutic point of view. This article studies a rare association of autoimmune diseases by discussing the pathophysiological hypotheses and an original therapeutic management. The coexistence of antineutrophil cytoplasmic antibody-associated vasculitis and spondyloarthritis has rarely been described.

Evaluation of Autologous Venous Allograft for Lower Limb in the Treatment of Critical Limb Ischemia. The REVATEC (REVAscularisation Par Greffons Veineux BioproTEC) Study.

Background: Critical limb threatening ischemia (CLTI) requires revascularization whenever it is possible. The great saphenous vein represents the surgical conduit of choice. However, it is not always available, in particular in multi-operated patients.

Histological pattern of non-infectious thoracic aortitis impacts mortality.

Background: Non-infectious aortitis encompasses various histological patterns, but their specific cardiovascular outcomes remain unclear.

Objective: To evaluate the mortality associated with non-infectious surgical thoracic aortitis.

Methods: This retrospective multicenter study included patients who underwent thoracic aortic surgery and had histological evidence of aortitis.

French protocol for the diagnosis and management of systemic lupus erythematosus.

Because Systemic Lupus Erythematosus (SLE) is a rare disease, and due to the significant prognostic impact of early management, a diagnosis confirmed by a physician with experience in SLE is recommended, for example from an expert center. Once the diagnosis is confirmed, existing manifestations should be identified in particular, renal involvement by an assessment of proteinuria, disease activity and severity should be determined, potential complications anticipated, associated diseases searched for, and the patient's socioprofessional and family context noted. Therapeutic management of SLE includes patient education on recognizing symptoms, understanding disease progression as well as when they should seek medical advice.

Impact of conventional and biological disease-modifying anti-rheumatic drugs on arterial lesions in Takayasu arteritis.

Background: The definition of Takayasu arteritis (TAK) remission and disease activity is still unclear. Vascular imaging is an essential tool for following-up patients. Herein, we aimed to compare the evolution of vascular lesions (i.

An interactive web application for exploring systemic lupus erythematosus blood transcriptomic diversity.

In the field of complex autoimmune diseases such as systemic lupus erythematosus (SLE), systems immunology approaches have proven invaluable in translational research settings. Large-scale datasets of transcriptome profiling have been collected and made available to the research community in public repositories, but remain poorly accessible and usable by mainstream researchers. Enabling tools and technologies facilitating investigators' interaction with large-scale datasets such as user-friendly web applications could promote data reuse and foster knowledge discovery.

Estimated prevalence, incidence and healthcare costs of Sjögren's syndrome in France: a national claims-based study.

Objectives: To estimate prevalence, incidence and mortality rates, and annual healthcare costs of primary Sjögren's syndrome (pSS) and SS associated with other autoimmune disorders (SS+AID) in France.

Methods: French national healthcare claims-based study within the prospective Système National des Données de Santé database that includes the majority of the French population. An algorithm was developed to identify patients with SS and SS-related healthcare claims were analysed between 2011 and 2018.